A Beginner’s Guide to Biotech Venture Capital

Biotechnology startup companies are unique from other startup ventures in that they have a high burn rate of capital and a long development process, making them very risky for investors. Novel biotechnology often faces legal and political battles during development (stem cells, mRNA vaccines) heightening the challenges that face burgeoning companies. Despite these risks, Venture Capital (VC) is a very important source of funding for biotechnology startups as it not only acts as a cash line, but also provides critical expertise that allow early-stage biotechnology companies to move through development and regulatory issues. So how does VC discern between good or bad investments? In this perspective, we will explore the characteristics of biotechnology companies that are evaluated by prospective VC partnerships. <a href="https://medium.com/mdplus/a-beginners-guide-to-biotech-venture-capital-13b6a5da395e">Click Here</a>